P
Pierre Tiberghien
Researcher at University of Franche-Comté
Publications - 323
Citations - 12112
Pierre Tiberghien is an academic researcher from University of Franche-Comté. The author has contributed to research in topics: Transplantation & Bone marrow. The author has an hindex of 55, co-authored 292 publications receiving 10671 citations. Previous affiliations of Pierre Tiberghien include French Institute of Health and Medical Research & Imperial College London.
Papers
More filters
Journal ArticleDOI
Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells
Zohair Selmani,Abderrahim Naji,Inès Zidi,Benoit Favier,Emilie Gaiffe,Laurent Obert,Christophe Borg,Philippe Saas,Pierre Tiberghien,Nathalie Rouas-Freiss,Edgardo D. Carosella,Frédéric Deschaseaux +11 more
TL;DR: It is reported that the nonclassic human leukocyte antigen (HLA) class I molecule HLA‐G is responsible for the immunomodulatory properties of MSCs and it is demonstrated that in addition to their action on the adaptive immune system, M SCs, through HLA•G5, affect innate immunity by inhibiting both NK cell‐mediated cytolysis and interferon‐γ secretion.
Journal ArticleDOI
Age of Transfused Blood in Critically Ill Adults
Jacques Lacroix,Paul C. Hébert,Dean Fergusson,Alan Tinmouth,Deborah J. Cook,John C. Marshall,Lucy Clayton,Lauralyn McIntyre,Jeannie Callum,Alexis F. Turgeon,Morris A. Blajchman,Timothy S. Walsh,Simon J. Stanworth,Helen Campbell,Gilles Capellier,Pierre Tiberghien,Laurent Bardiaux,Leo M.G. van de Watering,Nardo J. M. van der Meer,Elham Sabri,Abstr Act +20 more
TL;DR: Transfusion of fresh red cells, as compared with standard-issueRed cells, did not decrease the 90-day mortality among critically ill adults and there were no significant between-group differences in any of the secondary outcomes or in the subgroup analyses.
Journal ArticleDOI
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.
J. van Griensven,Tansy Edwards,X de Lamballerie,Malcolm G Semple,P Gallian,Sylvain Baize,Peter Horby,Hervé Raoul,N’Faly Magassouba,Annick Antierens,C Lomas,Oumar Faye,Amadou A. Sall,Katrien Fransen,Jozefien Buyze,Raffaella Ravinetto,Raffaella Ravinetto,Pierre Tiberghien,Yves Claeys,M De Crop,Lutgarde Lynen,Elhadj Ibrahima Bah,Pete Smith,Alexandre Delamou,A. De Weggheleire,Nyankoye Haba +25 more
TL;DR: The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing antibodies in 84 patients with confirmed EVD was not associated with a significant improvement in survival, and no serious adverse reactions associated with the use of convalscent plasma were observed.
Journal ArticleDOI
Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference
Markus M. Mueller,Hans Van Remoortel,Patrick Meybohm,Kari Aranko,Cecile Aubron,Reinhard Burger,Jeffrey L. Carson,Klaus Cichutek,Emmy De Buck,Dana V. Devine,Dean Fergusson,G. Folléa,Craig French,Kathrine P. Frey,Richard Gammon,Jerrold H. Levy,Michael F. Murphy,Yves Ozier,Katerina Pavenski,Cynthia So-Osman,Pierre Tiberghien,Jimmy Volmink,Jonathan H. Waters,Erica M. Wood,Erhard Seifried +24 more
TL;DR: The relative paucity of strong evidence to answer many of the PICO questions supports the need for additional research and an international consensus for accepted definitions and hemoglobin thresholds, as well as clinically meaningful end points for multicenter trials.
Journal ArticleDOI
Administration of herpes simplex–thymidine kinase–expressing donor T cells with a T-cell–depleted allogeneic marrow graft
Pierre Tiberghien,Christophe Ferrand,Bruno Lioure,Noel Milpied,Régis Angonin,Eric Deconinck,Jean-Marie Certoux,Eric Robinet,Philippe Saas,Bruno Petracca,Chris Juttner,Craig W. Reynolds,Dan L. Longo,Patrick Hervé,Jean-Yves Cahn +14 more
TL;DR: Overall, the administration of low numbers of HS-tk-expressing T cells early following an HLA-identical BMT is associated with no acute toxicity, persistent circulation of the GMCs, and GCV-sensitive GVHD, and open the way to the infusion of higher numbers of gene-modified donor T cells to enhance post-BMT immune competence while preserving GCv-sensitive alloreactivity.